Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

Seeking Alpha • Jun 1, 2026

RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study

Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.

Zacks Investment Research • Jun 1, 2026

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients ​live 15% longer than BeOne Medicines' Tevimbra immunotherapy.

Reuters • Jun 1, 2026

Revolution's pancreatic cancer drug doubles survival, boosts quality of life

Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients could resume ​activities they had previously abandoned, setting a new benchmark for this deadly cancer, researchers reported on Sunday.

Reuters • May 31, 2026

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine

GlobeNewsWire • May 31, 2026

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

GlobeNewsWire • May 21, 2026

GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and biotech.

Benzinga • May 19, 2026

Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease.

Benzinga • May 15, 2026

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from ​Revolution Medicines while they await what they hope will be a speedy FDA approval.

Reuters • May 14, 2026